CYTOKINETICS INC
CYTOKINETICS INC (CYTK): 95 pipeline candidates · 4 upcoming catalysts · ~16 mo cash runway · 16 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
16.3 months
D/E -2.54
Lead: Phase 3
95 candidates
4 upcoming, next in ~75d
0 buys · 44 sells (180d)
A transparent, data-derived signal for CYTOKINETICS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$10.6B
Cash
$133.0M
Quarterly Burn
$145.5M
Runway
16.3 mo
Revenue
$19.4M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (95 candidates)
| Drug | Phase |
|---|---|
| 14-day fecal molecular susceptibility-guided therapy | Phase 4 |
| 7-day fecal molecular susceptibility-guided therapy | Phase 4 |
| ACE inhibitor | N/A |
| ACP-196 | Phase 2 |
| Aficamten | Phase 3 |
| aficamten (5 mg | Phase 3 |
| Amoxicillin | Phase 2 |
| Anakinra | — |
| Anti-hypertensives | Phase 2 |
| azithromycin | — |
Showing 10 of 95 candidates. Sign up for full pipeline.
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
446
Total value held
$9.22B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 16,548,011 | $1.09B |
| vanguard capital management llc | 10,977,268 | $723.5M |
| fmr llc | 10,723,140 | $706.8M |
| wellington management group llp | 8,009,489 | $527.9M |
| vanguard portfolio management llc | 5,843,782 | $385.2M |
| state street corp | 5,745,193 | $378.7M |
| geode capital management, llc | 3,215,415 | $212.0M |
| bank of america corp /de/ | 3,125,436 | $206.0M |
| rtw investments, lp | 2,721,158 | $179.4M |
| armistice capital, llc | 2,664,538 | $175.6M |
Showing top 10 of 446 institutional holders of CYTOKINETICS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in CYTOKINETICS INC's pipeline?
CYTOKINETICS INC (CYTK) has 95 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CYTOKINETICS INC's lead drug candidate?
CYTOKINETICS INC's most advanced tracked candidate is 14-day fecal molecular susceptibility-guided therapy (Phase 4) for Bacterial Keratitis.
What is CYTOKINETICS INC's next catalyst?
CYTOKINETICS INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Afica" — expected September 1, 2026.
What is CYTOKINETICS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CYTOKINETICS INC has approximately 16.3 months of cash runway.
What is CYTOKINETICS INC's market capitalization?
CYTOKINETICS INC's market capitalization is approximately $10.6B.
Get the full picture on CYTOKINETICS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.